April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
21 citations
,
August 2002 in “British Journal of Ophthalmology” Intralesional cidofovir may be a viable alternative treatment for SCC.
3 citations
,
January 2025 in “Journal of Natural Products” Calancardin B may help reduce inflammation in immune cells.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
November 2025 in “Journal of Medicinal Chemistry” Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.
The cream with xyloglucan, pea protein, and cactus extract works as well as the standard treatment for psoriasis and is well-tolerated.
September 2023 in “Journal of the American Academy of Dermatology” ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.
Secukinumab treatment may cause HBV reactivation and hair discoloration.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
78 citations
,
June 2005 in “Annals of oncology” Cetuximab can cause excessive eyelash growth.
May 2026 in “Journal of Dermatological Treatment” Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.
July 2024 in “Journal of Investigative Dermatology”
5 citations
,
November 2024 in “Journal of Clinical Immunology” Dupilumab effectively controls symptoms in infants with Netherton syndrome.
December 2022 in “Pakistan Journal of Medical and Health Sciences” Tofacitinib effectively treats Alopecia Areata.
January 2018 in “Springer eBooks” Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
15 citations
,
June 1964 in “Experimental Biology and Medicine” Methotrexate can temporarily suppress certain immune responses without killing immune cells, potentially helping treat autoimmune diseases.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
19 citations
,
October 2011 in “Clinics in Dermatology” New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
July 2003 in “Pediatrics in review” In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.
2 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.